Literature DB >> 15620827

Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program.

Helio S Sader1, Mariana Castanheira, Rodrigo E Mendes, Mark Toleman, Timothy R Walsh, Ronald N Jones.   

Abstract

Carbapenem resistance among Pseudomonas aeruginosa and Acinetobacter spp. is becoming a critical therapeutic problem worldwide. The SENTRY Antimicrobial Surveillance Program monitors pathogen frequency and antimicrobial resistance patterns of nosocomial and community-acquired infections through sentinel hospitals on five continents. Pseudomonas spp. and Acinetobacter spp. strains resistant to imipenem (MIC, >/=16 mg/l), meropenem (MIC, >/=16 mg/l), and ceftazidime (MIC, >/=32 mg/l) collected from January 2001 to December 2003 were routinely screened for antimicrobial resistance genes. Resistant isolates were initially tested for metallo-beta-lactamase (MbetaL) production by phenotypic tests (disk approximation or MbetaL Etest strip) and then characterization of the MbetaL (hydrolysis assays, PCR for bla(IMP), bla(VIM), bla(SPM), gene sequencing). Eighty-nine isolates (33 Acinetobacter spp., 54 Pseudomonas aeruginosa, and 2 P. fluorescens) had positive phenotypic screening tests. Among those, 34 isolates producing MbetaL were identified, including 7 Acinetobacter spp., 25 P. aeruginosa and 2 P. fluorescens. The MbetaLs identified were IMP-1, VIM-2 and two newly described enzymes: SPM-1 and IMP-16. The greatest concentration of MbetaL strains was in Brazil, where imipenem-resistant P. aeruginosa increased significantly in the time period evaluated by the SENTRY Program. MbetaL-producing P. aeruginosa was detected in São Paulo (SPM-1) and Brasilia (SPM-1 and IMP-16), Brazil and Caracas, Venezuela (VIM-2); while MbetaL-producing Acinetobacter spp. isolates were detected in São Paulo, Brazil (IMP-1). P. fluorescens isolates producing IMP-1 and VIM-2 were detected in São Paulo, Brazil and Santiago, Chile, respectively. The emergence and dissemination of mobile MbetaL-producing isolates represent an alarming factor for increasing resistance to carbapenems in several medical centres evaluated by the SENTRY Program in Latin America.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15620827     DOI: 10.1016/j.ijantimicag.2004.08.013

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  20 in total

1.  Genetic and enzymatic properties of metallo-beta-lactamase VIM-5 from a clinical isolate of Enterobacter cloacae.

Authors:  Gulcin G Gacar; Kenan Midilli; Fetiye Kolayli; Kivanc Ergen; Sibel Gundes; Salih Hosoglu; Aynur Karadenizli; Haluk Vahaboglu
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States.

Authors:  K Lolans; A M Queenan; K Bush; A Sahud; J P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis.

Authors:  Rodrigo E Mendes; Katia A Kiyota; Jussimara Monteiro; Mariana Castanheira; Soraya S Andrade; Ana C Gales; Antonio C C Pignatari; Sergio Tufik
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

4.  First detection of metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from Colombia.

Authors:  Maria Virginia Villegas; Karen Lolans; Maria del Rosario Olivera; Carlos José Suarez; Adriana Correa; Anne Marie Queenan; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.

Authors:  U Garza-Ramos; R Morfin-Otero; H S Sader; R N Jones; E Hernández; E Rodriguez-Noriega; A Sanchez; B Carrillo; S Esparza-Ahumada; J Silva-Sanchez
Journal:  Antimicrob Agents Chemother       Date:  2008-05-19       Impact factor: 5.191

6.  Detection of VIM- and IMP-type Metallo-Beta-Lactamase Genes in Acinetobacter baumannii Isolates from Patients in Two Hospitals in Tehran.

Authors:  Saba Davoodi; Mohammad Ali Boroumand; Saeed Sepehriseresht; Leila Pourgholi
Journal:  Iran J Biotechnol       Date:  2015-03       Impact factor: 1.671

7.  In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Samuel K Bouchillon; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

8.  Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. in Europe.

Authors:  Sophie Marqué; Laurent Poirel; Claire Héritier; Sylvain Brisse; Maria Dolores Blasco; Roxana Filip; Gabriela Coman; Thierry Naas; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

9.  Metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa in a Brazilian university hospital.

Authors:  Maria Renata Gomes Franco; Hélio Hehl Caiaffa-Filho; Marcelo Nascimento Burattini; Flávia Rossi
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

Review 10.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.